CA
NZ
UK
AU
IND
US
Bio-Techne Corporation (NASDAQ: TECH) reported an earnings per share (EPS) of $0.53 for the quarter ending March 31. This figure slightly beats analysts' expectations, which had set the consensus at $0.55. The positive deviation indicates strong operational performance within the life sciences sector, where …
Arbutus Biopharma Corporation (NASDAQ: ABUS) reported a significant $178 million financial uplift from its recent settlement with Moderna, Inc. This payment stems from a larger $950 million agreement overPatentinfringement related to lipid nanoparticle technology. The settlement not only alleviates a vital pressure point for …
The cash balance, down from $91.2 million three months earlier, is projected to sustain operations through late 2027.
Achieve Life Sciences (NASDAQ: ACHV) raised $180 million upfront from a $354 million private placement, delivering a sizeable cash boost that underwrites its upcoming FDA resubmission. The infusion arrives as the company reports an EPS of $‑0.19, outperforming the $‑0.31 consensus, and positions it …
The UK's Medicines and Healthcare products Regulatory Agency granted a marketing authorization on 10 August 2026 for orforglipron, which Eli Lilly (NYSE:LLY) sells under theBrandname Foundayo. Two indications came through, not one. The tablet is licensed for weight loss and weight maintenance in adults …
Timing is rarely this pointed. Novo Nordisk (NYSE:NVO) launched its Wegovy pill in the UK at the start of July and, on the company's own account, roughly 300,000 British patients started treatment within three weeks, lifting its share of the domestic obesity market from …
Alcon's (NYSE:ALC) second quarter, published from Geneva on Monday, brought $2.78 billion of net sales against $2.58 billion a year earlier, up 8% as reported and 7% at constant currency, with roughly a percentage point of help from a weaker dollar. That edged past …
Novo Nordisk (NYSE:NVO) shares were trading at $45.97 in pre-market activity on August 12, 2026, down 2.55% from the prior close of $47.17. The decline follows a ratings downgrade to Hold from Buy, with the covering research firm also cutting its price target to …
Taysha Gene Therapies (NASDAQ:TSHA) shares were trading at $6.13 in pre-market activity on August 12, 2026, down 8.31% from the prior close of $6.68. The decline gives back much of Tuesday's 4.87% post-earnings rally, as investors digest a wider-than-expected quarterly loss alongside otherwise encouraging …
Eli Lilly (NYSE:LLY) shares were trading at $1,213.10 in pre-market activity on August 12, 2026, down 0.13% from the prior close of $1,215.02. The muted move comes as investors digest the company's aggressive legal crackdown on the illegal retatrutide black market, with Lilly filing …
Please wait processing your request...